Reading the semaglutide package insert: a plain-English guide to the Wegovy patient leaflet

Step 1 (find the right document: PIL versus SmPC

Inside the outer Wegovy carton you will find two documents: the Patient Information Leaflet (PIL), written for you, and) if you look it up online, the Summary of Product Characteristics (SmPC), written for healthcare professionals. Both originate from the same regulatory submission to the MHRA, but the SmPC goes further into pharmacokinetics, clinical-trial data and prescribing contraindications. For most practical questions (how do I store this pen, what do I do if I'm sick after an injection, what are the warning signs I must not ignore) the PIL is the right starting point. You can read the current Wegovy SmPC on the Electronic Medicines Compendium (eMC), where it is updated whenever Novo Nordisk submits a variation to the MHRA. The version in your box applies specifically to your batch; always cross-check the leaflet in your hand with any online summary you find, because dosing schedules and storage windows can be updated between print runs.

One thing worth knowing: the outer packaging carries the batch number and expiry date; the PIL inside carries the document version date. If the two feel inconsistent, contact your dispensing pharmacy.

Step 2, how the titration schedule reads in the leaflet

The semaglutide package insert sets out a stepped dose schedule starting at 0.25 mg once weekly for the first four weeks. That starting dose is purely a tolerability measure; it lets your digestive system adjust before any meaningful weight-management effect begins. The leaflet then describes increases through 0.5 mg, 1.0 mg and 1.7 mg, arriving at the 2.4 mg maintenance dose, each step separated by roughly four weeks, at your prescriber's direction. The MHRA has also approved a higher 7.2 mg maintenance dose (the single-dose pen was authorised on 14 April 2026), and the PIL for that presentation carries its own titration detail.

The insert is explicit that dose changes are a clinical decision: you do not move up simply because four weeks have passed. If side effects are still troublesome at a given level, the leaflet advises staying there longer and discussing it with your prescriber. Our overview of how Wegovy works covers the mechanism behind those tolerability steps in plain terms. For the physical process of using the pen itself, the injection technique guide goes through each step in detail. The NHS also publishes patient-level information on semaglutide that complements the PIL well.

Step 3, the side-effect and warning sections (the parts most people skip)

The side-effect section of the Wegovy package insert is long, which can feel alarming. It is worth reading it at a steady pace rather than scanning for the worst entry. Common effects (nausea, loose stools, constipation, indigestion, tiredness) tend to cluster around the weeks immediately after a dose increase and usually settle without stopping treatment. The leaflet asks you to tell your prescriber or pharmacist if they persist.

Two sections deserve particular attention. First, pancreatitis: the insert asks you to seek urgent medical help for severe, persistent stomach pain that spreads towards your back, with or without vomiting. The MHRA issued a Drug Safety Update in January 2026 reinforcing this for all GLP-1 medicines; it is worth filing that symptom description somewhere you will remember it. Second, the leaflet covers allergic reactions, gallbladder symptoms, and (for people with diabetic eye disease) sudden vision changes, all listed as reasons to contact a healthcare professional promptly rather than waiting for a routine review.

The leaflet also contains a Yellow Card prompt. If you experience a side effect that feels unusual or severe, you can report it at yellowcard.mhra.gov.uk, this is how the MHRA continues to monitor safety after a medicine reaches patients.

Step 4, storage, travel and the room-temperature rule

Storage instructions in the Wegovy package insert are precise and batch-specific. The general principle (refrigerate at 2–8°C, keep away from the freezer, protect from light) applies across presentations, but the permitted room-temperature window (the number of days a pen can spend outside the fridge without being discarded) is stated in your own leaflet for a reason: it can differ between product generations. Always read your leaflet rather than relying on a figure you recall from a website, including this one.

A practical note: most people keep the pen in the fridge door next to everyday items, which is fine as long as it does not freeze. Before a trip, check the room-temperature allowance in your leaflet against your planned travel duration. The packaging and presentation guide has more on what arrives in the box and what to expect. On the question of what you can and cannot do while on semaglutide (including drinking, for example) the alcohol and Wegovy page covers what the clinical evidence says.

If you are considering Wegovy and want to understand the cost picture before starting, that context is available separately. Treatment is a prescription-only process, and our prescribers are available seven days a week. If you have questions about your leaflet or your treatment, speak to our prescribers through a free consultation, it costs nothing to ask.